The extracellular matrix (ECM) 
INTRODUCTION
During the last few years it has become more and more apparent that the biological activities of cytokines can not be sufficien.tly described by their interactions with the corresponding signaling receptors alone. Instead, it appears that in many, if not most cases cytokines and the extracellular matrix (ECM) cooperate in forming an "information network" that regulates such fundamental processes as cell proliferation, differentiation and apoptosis.
The ECM is a complex supramolecular structure composed of different types of macromolecules which are predominantly linked by non-covalent bonds. The major constituents are the collagens, the non-collagenous glycoproteins, elastin, hyaluronan and the proteoglycans. With the exception of elastin (and hyaluronan) , all the other classes consist of dif-ferent families of related proteins which are derived from individual genes. They can be expressed in a tissue specific and developmentally distinct manner and can therefore form matrices with particular physical as well as biological properties which are tailored for their distinct biological functions as well as for specific interactions with the embedded cells. These interactions are mediated by cell surface receptors for matrix proteins which can be integrins (Hynes, 1992) or non-integrin-receptors (Shrivastava et al., 1997) . The activation of these receptors by the ECM can influence the intracellular signal transduction and the expression of genes. By these means the matrix directly participates in the control of cell proliferation and differentiation as well as the survival of the cells (Frisch and Ruoslahti, 1997) .
Another important factor in the control of cell behaviour are soluble mediators like cytokines. For the purpose of this review we want to use this term not only for the classical cytokines but also for growth factors, because similar rules apply for their interactions with ECM molecules. The relationships between cytokines and the extracellular matrix are manyfold.
(1) Cytokines can influence the expression (Kovacs and DiPietro, 1994; Grande et al., 1997) and the turnover (Galis et al., 1994; of specific ECM molecules. (2) Certain matrix derived peptides can mediate the synthesis of cytokines (Lopez-Moratalla et al., 1995) . (3) Cytokines can be dependent on ECM molecules as co-receptors (Rapraeger et al., 1991; Yayon et al., 1991) or (4) matrix cell surface receptors like integrins may be needed for the clustering of cytokine receptors to cause an effective signal transduction (Schneller et al., 1997) . (5) Cytokines can use intracellular signal transduction pathways that are similar to the ways activated by matrix receptors (Schlaepfer et al., 1994; Short et al., 1998 residues that can be sulfated in the C4-and/or C6-position of the N-acetyl galactosamine residues. In dermatan sulfate the glucuronic acid is additionally epimerized to iduronic acid. The initial polysaccharide backbone of heparan sulfate and heparin consists of alternating N-acetyl glucosamine and glucuronic acid residues. This structure subsequently becomes modified by a series of reactions, each one creating the substrate structure for the next modifying step. The first modification is N-deacetylation and subsequent N-sulfation of N-acetyl glucosamine residues, both reactions being carried out by the same enzyme. In heparan sulfate these reactions are restricted to characteristic domains, leaving parts of the chain essentially unmodified, whereas in heparin these modifications run more towards completion. Subsequent modifications include the epimerization of glucuronic acid to iduronic acid, the sulfation of 20 of glucuronic acid (rare) and iduronic acid residues and the sulfation of 60 and 30 (rare) of glucosamine residues. The consequence of the incompleteness of each modifying step is the generation of an enormous structural heterogeneity in the modified domains 'of the heparan sulfate chain, leading to the potential for a great variety of specific interactions (Hardingham and Fosang, 1992) . Finally, keratan sulfate chains are composed of alternating N-acetyl glucosamine and galactose residues that can be O-sulfated at C6 of either sugar (Fig. 1 ). Giypieansa:
Glypican-5 (Selleck, 1998 (Lopez-Casillas et al., 1993) . Another example is provided by the chondroitin sulfate proteoglycan NG2, which modulates the biological activity of platelet-derived growth factor AA (PDGF-AA) by interacting with the PDGF-a receptor (Grako and Stallcup, 1995) . Indeed, NG2 has to be present for effective signal transduction via the PDGF-o receptor, as this receptor cannot be autophosphorylated in cells from NG2 (-/-) mice (Grako et al., 1999) .
The matrix associated proteoglycans can be classified according to size, distribution and sequence similarities of their core proteins (Table I ). Perlecan and agrin are large modular proteoglycans which are integrating constituents of basement membranes. The modular structure of their core proteins allows them to interact with a variety of other components of the basement membrane, thus contributing to the structural integrity of this specialized type of ECM. With the negative charge of their heparan sulfate chains, they contribute to the charge selectivity of the glomerular basement membrane. Additionally, these chains can interact with heparin-binding cytokines, mediating storage of these cytokines in the ECM (Iozzo, 1994) .
Another group of large matrix associated proteoglycans, that are not constituents of basement membranes, are the members of the aggrecan family: aggrecan, versican, neurocan and brevican. They possess a binding site for hyaluronan at the N-terminus of their core protein and a lectin-like domain at the C-terminus. Therefore, they are suited to form a link between hyaluronan in the ECM and glycoproteins and glycolipids on the cell surface (Miura et al., 1999) . In addition, they contain EGF-like domains which have been shown to mediate cell proliferation in fibroblasts (Zhang et al., 1998) . Apparently, these matrix molecules exhibit cytokine-like activities by themselves.
The largest group of the matrix associated proteoglycans are the small leucine-rich repeat proteoglycans. Eight different members of this family have been described so far. As in other proteins containing the leucine-rich repeat motif, this structure is expected to mediate protein-protein interactions in these proteoglycans, too  Iozzo, 1997; Hocking et al., 1998 ). The prototype member of the leucine-rich repeat proteoglycans is decorin which has a core protein of about 36 kDa, either two or three N-linked oligosaccharides and a single chondroitin/dermatan sulfate chain in mammals. Decorin received its name because it binds to the surface of collagen fibrils, thus "decorating" the fibrils. In addition to binding to different types of collagen, it can also interact with a variety of other ECM molecules, such as fibronectin and thombospondin, as well as with C lq and with different members of the TGF-I] family. Whereas most of these interactions are mediated by the core protein, the GAG chain is also able to interact with other molecules, such as with heparin cofactor II (Whinna et al., 1993 (Felix et al., 1996) . Many other cells have been shown to synthesize CSF-1, but it has not been determined whether the cytokine is released in its proteoglycan form or in, its mature form, which is a homodimer of 85 kDa. This homodimer is generated by partial proteolysis of the C-terminus which contains the GAG chain. It has not been clarified so far whether this cleavage reaction occurs due to an autocatalytic activity of PG-100 itself, or whether other proteases are involved in this step. Comparison of the growth stimulatory effect of PG-100 and the mature CSF-1 showed that the proteoglycan form is less active (Partenheimer et al., 1995) . Therefore, the proteoglycan form could be a storage form of the cytokine which is bound via its GAG chain to ECM molecules , Ohtsuki et al., 1993 and which can be released by proteolytic degradation of the matrix. In addition, the proteoglycan form but not the mature form can bind FGF-2. Peptides of the core protein of PG-100, which mediate this binding, can inhibit the growth-stimulatory effect of FGF-2 (Suzu, et al., 1997 (Massagu6, 1998) . The importance of TGF-1 for the immune system has become especially evident when TGF-(-/-) mice were generated by targeted gene disruption. Only about half of these mice were normally born and two weeks after birth they developed a wasting syndrome with multiple inflammatory lesions in almost all organs without exposure to a pathogen, indicating an autoimmune reaction Boivin et al., 1995 (Hildebrand et al., 1994) . All these three small proteoglycans appear to compete with betaglycan for the same binding site on the TGF-dimer (Fukushima et al., 1993) . However, the consequences of this interaction is still a matter of debate. Whereas some investigators suggested a direct inactivation of TGF-[ by decorin (Yamaguchi and Ruoslahti, 1988; Yamaguchi et al., 1990) , others found no change in TGF-[3 activity (Hausser et al., 1994) or even an activation of TGF-[3 (Takeuchi et al., 1994) (Hausser et al., 1989 ) present at the cell surface of many cells could be envisaged as a further possibility for decorin to influence TGF-activity. If, for instance, the decorin/TGF-[3 complex would be a substrate for endocytosis, decorin could mediate the clearance of extracellular TGF-I, thereby decreasing its activity. Whether the decorin/TGF-complex is able to bind to the endocytosis receptor has so far not been investigated. However, the observation that both, binding of decorin to its receptor and binding of TGF-to decorin can be inhibited by an antibody directed against the central region of the decorin core protein (aa 155-260 of pre-pro decorin) argues for a close spatial relationship of the two binding sites (Hausser et al., 1998; Sch6nherr et al., 1998) .
Not only the activity of TGF-is affected by molecules of the ECM, TGF-I3 itself has a profound effect on the synthesis and degradation of a large number of ECM molecules. A stimulation of the synthesis of fibronectin, different types of collagen, thrombospondin, laminin, some proteoglycans, tissue inhibitors of metalloproteinases, integrins etc. as well as the inhibition of the expression of metalloproteinases together lead to an increased deposition of ECM (Massagu6, 1990) . Such an increased ECM deposition by resident and/or invading cells is necessary during wound healing (Sporn and Roberts, 1992) . In chronic inflammation, however, excessive ECM synthesis can lead to fibrosis with concomitant destruction of normal organ function (Okuda et al., 1990; Border and Noble, 1994 (Border et al., 1992) as well as a gene therapeutic approach with decorin cDNA (Isaka et al., 1996) (Wahl et al., 1987) (Fernig and Gallagher, 1994; Ohbayashi et al., 1998) . It plays part in such important physiological processes as embryonic development, angiogenesis, neuronal differentiation and wound repair, being involved in the regulation of migration, proliferation and differentiation of numerous cell types. Even though it shares only 10% sequence identity with interleukin 1, the tertiary structure of these two molecules is identical (Zhang et al., 1991) . The relationship between the "growth factor" FGF-2 and "classical" cytokines, however, is not only a structural one. In concert with other soluble factors, it participates in positively regulating hematopoesis by acting on stromal cells as well as on early and committed hematopoetic progenitors, preventing apoptosis and leading to an increased cell proliferation and cytokine secretion (Allouche, 1995) . This is achieved by acting synergistically with numerous hematopoetic cytokines as well as by antagonizing the effects of TGF-I.
Members of the FGF family exert their biological effects by binding t four structurally related high-affinity FGF receptors (Friesel and Maciag, 1995; Klint and Claesson-Welsh, 1999) . These polypeptides contain an extracellular domain composed of up to three immunoglubulin-like domains, a transmembrane domain and an intracellular tyrosine kinase domain. By alternative splicing, structural variants are generated that differ in their ligand-binding specificities and affinities. In addition to these high-affinity signaling receptors, it has been recognized for long time that FGF-2 (and the other members of the FGF family) binds with lower affinity to heparan sulfate chains present in the ECM and on the cell surface. This interaction not only leads to a sequestration of the cytokine within the ECM and to its stabilization and protection from inactivation (Vlodavsky et al., 1996) . It is also required for the cytokine to exert its biological activity (Yayon et al., 1991; Rapraeger et al., 1991) .
The minimal binding structure on the heparan sulfate chain has been revealed to be a pentasaccharide containing at least one iduronic acid residue sulfated at C2 and one or two N-sulfate groups Faham et al., 1996) . Additional sulfate groups, either at C2 of iduronic acid or at C6 of glucosamine, are not required for binding and do not interfere with binding. For stimulation of the mitogenic activity of FGF-2, however, a sequence of at least 12 saccharides containing sulfate groups at C2 of iduronic acid as well as at C6 of glucosamine is necessary (Guimond et al., 1993 (Turnbull and Gallagher, 1993; Salmivirta et al., 1996) . Indeed, the receptor has been shown to be able to interact with heparan sulfate (Kan et al., 1993) , and this interaction can lead to an activation of the receptor, even in the absence of cytokine (Gao and Goldfarb, 1995) . The observation of additional structural requirements for activation in comparison with FGF-2 binding alone is in support of the third model, postulating the formation of a ternary complex as the signaling complex. There are two important predictions derived from this model: (1) depending on the spacing of the two binding sites for receptor and FGF-2 on the GAG chain, interaction of the cytokine with heparan sulfate will either promote or inhibit its cellular response and (2) the fine structure of the heparan sulfate chain will determine which of the heparin-binding cytokines will be activated, provided that different cytokines possess different binding requirements. Indeed, different fine structures appear to be necessary for activation of FGF-1, FGF-2 and FGF-4 (Guimond et al., 1993) . Therefore, by changing the fine structures of their cell surface heparan sulfates, cells may select the cytokine to be activated. This might be achieved either by substituting existing heparan sulfate proteoglycans with newly synthesized ones or by modification of the GAG chains during recycling of proteoglycans (Fransson et al., 1995) . In the developing neuroepithelium, cell surface associated heparan sulfate proteoglycans carry chains that are able to bind and activate FGF-2 on day 9 (Nurcombe et al., 1993) . Two days later, with the onset of FGF-1 expression, the fine structure of newly synthesized heparan sulfate chains is changed, allowing binding and activation of FGF-1. At this time, the more differentiated cells synthesize longer heparan sulfate chains containing more modified domains with a higher content of disaccharide units sulfated at C2 of the iduronic acid and, importantly, at C6 of the glucosamine residues (Brickman et al., 1998a; Brickman et al., 1998b) . Sulfation at C6 of glucosamine appears to be required for binding of FGF-1 (Fromm et al., 1997) .
Obviously, due to the fact that cytokine activation requires the formation of a ternary complex of cytokine, receptor and heparan sulfate, "activating" heparan sulfate chains have to be in close proximity of the receptor molecules. Therefore, chains of matrix associated proteoglycans that are remote from the signaling receptors will sequester the cytokine within the ECM, actually leading to its inactivation, provided they possess the appropriate binding structures. Upon proteolytic degradation of the matrix or upon degradation of the heparan sulfate chains by released heparanases, these bound cytokines however may become available for signaling. On the contrary, cytokine bound to cell surface associated heparan sulfate proteoglycans may become inactivated due to the shedding of the respective proteoglycan molecules, either by proteolytic cleavage of a juxtamembraneous cleavage site in the case of syndecans or by cleavage of the GPI anchor in the case of the glypicans. Thus, in addition to factors controlling release and degradation, a complex interplay involving the regulated synthesis and distribution of heparan sulfate proteoglycans as well as the regulated activities of extracellular enzymes acting on these proteoglycans determines the availability and biological activity of heparan-sulfate binding cytokines.
